Context Therapeutics (NASDAQ:CNTX) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Context Therapeutics (NASDAQ:CNTX) from a sell rating to a strong sell rating in a report released on Monday.

CNTX has been the topic of a number of other research reports. Maxim Group dropped their price objective on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Piper Sandler raised their price target on shares of Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Guggenheim reaffirmed a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a research note on Tuesday, March 24th. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, March 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $6.17.

Context Therapeutics Price Performance

Shares of NASDAQ CNTX opened at $0.61 on Monday. Context Therapeutics has a 1-year low of $0.55 and a 1-year high of $3.62. The company has a market capitalization of $56.36 million, a price-to-earnings ratio of -1.46 and a beta of 1.75. The business has a 50-day moving average of $1.32 and a 200-day moving average of $2.00.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. Research analysts expect that Context Therapeutics will post -0.39 EPS for the current fiscal year.

Institutional Trading of Context Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CNTX. Seven Fleet Capital Management LP acquired a new stake in Context Therapeutics during the first quarter valued at approximately $500,000. Bank of America Corp DE grew its position in shares of Context Therapeutics by 12,213.8% in the 1st quarter. Bank of America Corp DE now owns 114,888 shares of the company’s stock worth $301,000 after acquiring an additional 113,955 shares in the last quarter. Octagon Capital Advisors LP acquired a new position in shares of Context Therapeutics in the 1st quarter worth approximately $13,755,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Context Therapeutics in the 1st quarter valued at approximately $211,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Context Therapeutics in the 1st quarter valued at approximately $51,000. 14.03% of the stock is owned by institutional investors.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.